Contributions of gene marking to cell and gene therapies

Human Gene Therapy

Volumn 22, Issue 6, 2011, Pages 659-668

  Barese, Cecilia N ^a   Dunbar, Cynthia E ^a,b  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 BIS (2 CHLOROETHYL) 1 NITROSOUREA; 6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; AP 1903; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; RETROVIRUS VECTOR; TREMOZOLOMIDE; UNCLASSIFIED DRUG;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL THERAPY; CHRONIC MYELOID LEUKEMIA; DRUG DOSE ESCALATION; GENE THERAPY; GENE TRANSFER; GENOTOXICITY; HODGKIN DISEASE; HUMAN; IN VIVO STUDY; LYMPHOMA; MARKER GENE; MELANOMA; METASTASIS; NEUROBLASTOMA; NONHUMAN; T CELL LEUKEMIA; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD19; DRUG RESISTANCE, NEOPLASM; GENE THERAPY; GENETIC MARKERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; RECEPTOR, NERVE GROWTH FACTOR; T-LYMPHOCYTES;

ANIMALIA; MURINAE;

EID: 79958234570     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2010.237     Document Type: Article

References (103)

1. Aiuti, A., Cattaneo, F., Galimberti, S., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med. 360, 447-458.
2. Aiuti, A., Slavin, S., Aker, M., et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with non-myeloablative conditioning. Science 296, 2410-2413. (Pubitemid 34734219)
3. \+ cells after autologous stem cell transplantation for multiple myeloma. Cancer Gene Ther. 14, 227-232.
4. Bachier, C.R., Giles, R.E., Ellerson, D., et al. (1999). Hemato-poietic retroviral gene marking in patients with follicular non-Hodgkin's lymphoma. Leuk. Lymphoma 32, 279-288. (Pubitemid 29087809)
5. Baum, C. (2007). Insertional mutagenesis in gene therapy and stem cell biology. Curr. Opin. Hematol. 14, 337-342. (Pubitemid 46842807)
6. Baum, C., Dullmann, J., Li, Z., et al. (2003). Side effects of ret-roviral gene transfer into hematopoietic stem cells. Blood 101, 2099-2114. (Pubitemid 36302043)
7. Beard, B.C., Trobridge, G.D., Ironside, C., et al. (2010). Efficient and stable MGMT-mediated selection of long-term re-populating stem cells in nonhuman primates. J. Clin. Invest. 120, 2345-2354.
8. Bennour, E., Ferrand, C., Remy-Martin, J.P., et al. (2008). Abnormal expression of only the CD34 part of a transgenic CD34/herpes simplex virus-thymidine kinase fusion protein is associated with ganciclovir resistance. Hum. Gene Ther. 19, 699-709. (Pubitemid 352009909)
9. Blaese, R.M., Culver, K.W., Miller, A.D., et al. (1995). T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 270, 475-480.
10. Bollard, C.M., Heslop, H.E., and Brenner, M.K. (2001). Gene-marking studies of hematopoietic cells. Int. J. Hematol. 73, 14-22. (Pubitemid 33758834)
11. Bonini, C., Bondanza, A., Perna, S.K., et al. (2007). The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther. 15, 1248-1252. (Pubitemid 46965319)
12. Bonini, C., Ferrari, G., Verzeletti, S., et al. (1997). HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719-1724. (Pubitemid 27421983)
13. Bonini, C., Grez, M., Traversari, C., et al. (2003). Safety of ret-roviral gene marking with a truncated NGF receptor. Nat. Med. 9, 367-369. (Pubitemid 36460048)
14. Bordignon, C., Notarangelo, L.D., Nobili, N., et al. (1995). Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270, 470-475.
15. Bosticardo, M., Ghosh, A., Du, Y., et al. (2009). Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells. Mol. Ther. 17, 1910-1918.
16. Boztug, K., Schmidt, M., Schwarzer, A., et al. (2010). Stem-cell gene therapy for the Wiskott-Aldrich syndrome. N. Engl. J. Med. 363, 1918-1927.
17. Brenner, M.K., Rill, D.R., Holladay, M.S., et al. (1993a). Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet 342, 1134-1137. (Pubitemid 23324053)
18. Brenner, M.K., Rill, D.R., Moen, R.C., et al. (1993b). Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341, 85-86. (Pubitemid 23028118)
19. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
20. Cassani, B., Montini, E., Maruggi, G., et al. (2009). Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 114, 3546-3556.
21. Cavazzana-Calvo, M., Hacein-Bey, S., de Saint Basile, G., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 288, 669-672. (Pubitemid 30241569)
22. Cavazzana-Calvo, M., Payen, E., Negre, O., et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318-322.
23. Ciceri, F., Bonini, C., Marktel, S., et al. (2007). Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109, 4698-4707. (Pubitemid 46827761)
24. Cornetta, K., Tricot, G., Broun, E.R., et al. (1992). Retroviral-mediated gene transfer of bone marrow cells during autolo-gous bone marrow transplantation for acute leukemia. Hum. Gene Ther. 3, 305-318.
25. Dao, M.A., Hashino, K., Kato, I., and Nolta, J.A. (1998). Adhesion to fibronectin maintains regenerative capacity during ex-vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood 92, 4612-4621. (Pubitemid 29005863)
26. Deisseroth, A.B., Zu, Z., Claxton, D., et al. (1994). Genetic marking shows that Ph\+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83, 3068-3076. (Pubitemid 24142743)
27. Dick, J.E., Magli, M.C., Huszar, D., et al. (1985). Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice. Cell 42, 71-79. (Pubitemid 16237557)
28. Di Stasia, A., Tey, S.K., Fujita, Y., et al. (2010). CASPALLO: Phase I clinical trial of allodepleted T cells transduced with inducible caspase 9 suicide gene after haploidentical stem cell transplantation. Mol. Ther. 18, Abs. 288.
29. Donahue, R.E., and Dunbar, C.E. (2001). Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum. Gene Ther. 12, 607-617. (Pubitemid 32506940)
30. Dunbar, C.E., Cottler-Fox, M., O'Shaughnessy, J.A., et al. (1995). Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 85, 3048-3057.
31. \+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9, 2629-40. (Pubitemid 29004635)
32. Dunbar, C.E., Seidel, N.E., Doren, S., et al. (1996). Improved retroviral gene transfer into murine and Rhesus peripheral blood or bone marrow repopulating cells primed in vivo with stem cell factor and granulocyte colony-stimulating factor. Proc. Natl. Acad. Sci. U. S. A. 93, 11871-11876. (Pubitemid 26347216)
33. \+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. Blood 89, 4040-4046. (Pubitemid 27220949)
34. Fehse, B., Kustikova, O.S., Li, Z., et al. (2002). A novel 'sort-suicide' fusion gene vector for T cell manipulation. Gene Ther. 9, 1633-1638. (Pubitemid 35414526)
35. Fehse, B., Richters, A., Putimtseva-Scharf, K., et al. (2000). CD34 splice variant: an attractive marker for selection of gene-modified cells. Mol. Ther. 1, 448-456.
36. Ferrari, G., Rossini, S., Giavazzi, R., et al. (1991). An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251, 1363-1366. (Pubitemid 21916921)
37. Ferrari, G., Rossini, S., Nobili, N., et al. (1992). Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions. Blood 80, 1120-1124.
38. Gabriel, R., Eckenberg, R., Paruzynski, A., et al. (2009). Comprehensive genomic access to vector integration in clinical gene therapy. Nat. Med. 15, 1431-1436.
39. Gaspar, H.B., Bjorkegren, E., Parsley, K., et al. (2006). Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. Mol. Ther. 14, 505-513. (Pubitemid 44339393)
40. Gaspar, H.B., Parsley, K.L., Howe, S., et al. (2004). Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364, 2181-2187. (Pubitemid 40018447)
41. Gerrits, A., Dykstra, B., Kalmykowa, O.J., et al. (2010). Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood 115, 2610-2618.
42. Gerull, S., Beard, B.C., Peterson, L.J., et al. (2007). In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum. Gene Ther. 18, 451-456. (Pubitemid 46850136)
43. Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302, 415-419. (Pubitemid 37296260)
44. Hackett, P.B., Largaespada, D.A., and Cooper, L.J. (2010). A transposon and transposase system for human application. Mol. Ther. 18, 674-683.
45. Hanawa, H., Hematti, P., Keyvanfar, K., et al. (2004). Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a simian immunodeficiency virus-based lentiviral vector system. Blood 103, 4062-4069. (Pubitemid 38685345)
46. Hanazono, Y., Yu, J.M., Dunbar, C.E., and Emmons, R.V. (1997). Green fluorescent protein retroviral vectors: low titer and high recombination frequency suggest a selective disadvantage. Hum. Gene Ther. 8, 1313-1319. (Pubitemid 27445412)
47. Hanenberg, H., Xiao, X.L., Dilloo, D., et al. (1996). Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat. Med. 2, 876-882. (Pubitemid 26296757)
48. Hawley, T.S., Telford, W.G., and Hawley, R.G. (2001). "Rainbow" reporters for multispectral marking and lineage analysis of hematopoietic stem cells. Stem Cells 19, 118-124. (Pubitemid 32222236)
49. Hayakawa, J., Ueda, T., Lisowski, L., et al. (2009). Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. Hum. Gene Ther. 20, 563-572.
50. \+ selected marrow cells in patients undergoing autologous bone marrow transplantation. Hum. Gene Ther. 7, 655-667. (Pubitemid 26105919)
51. Heslop, H.E., and Rooney, C.M. (1997). Adoptive cellular im-munotherapy for EBV lymphoproliferative disease. Immunol. Rev. 157, 217-222. (Pubitemid 27303131)
52. Heslop, H.E., Slobod, K.S., Pule, M.A., et al. (2010). Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115, 925-935.
53. Hoogerbrugge, P.M., van Beusechem, V.W., Fischer, A., et al. (1996). Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther. 3, 179-183. (Pubitemid 26117428)
54. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
55. Hu, J., and Dunbar, C.E. (2002). Update on hematopoietic stem cell gene transfer using non-human primate models. Curr. Opin. Mol. Ther. 4, 482-490. (Pubitemid 36305041)
56. Hu, J., Ferris, A., Larochelle, A., et al. (2007). Transduction of rhesus macaque hematopoietic stem and progenitor cells with avian sarcoma and leukosis virus vectors. Hum. Gene Ther. 18, 691-700. (Pubitemid 47378066)
57. Hu, J., Renaud, G., Gomes, T.J., et al. (2008). Reduced geno-toxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retro-virus vectors. Mol. Ther. 16, 1617-1623.
58. Huhn, R.D., Tisdale, J.F., Agricola, B., et al. (1999). Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum. Gene Ther. 10, 1783-1790. (Pubitemid 29357684)
59. Kiem, H.P., Andrews, R.G., Morris, J., et al. (1998). Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combi-nation with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood 92, 1878-1886. (Pubitemid 28446676)
60. \+ cells. Blood 113, 5434-5443.
61. Kohn, D.B. (2008). Gene therapy for childhood immunological diseases. Bone Marrow Transplant 41, 199-205. (Pubitemid 351188918)
62. Kohn, D.B., Weinberg, K.I., Nolta, J.A., et al. (1995). Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med. 1, 1017-1023.
63. Kuramoto, K., Follmann, D.A., Hematti, P., et al. (2004). Effect of chronic cytokine therapy on clonal dynamics in nonhuman primates. Blood 103, 4070-4077. (Pubitemid 38685346)
64. Kustikova, O., Fehse, B., Modlich, U., et al. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171-1174. (Pubitemid 40696434)
65. Larochelle, A., Choi, U., Shou, Y., et al. (2009). In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduc-tion with a drug resistance gene. J. Clin. Invest. 119, 1952-1963.
66. Laukkanen, M.O., Kuramoto, K., Calmels, B., et al. (2005). Low-dose total body irradiation causes clonal fluctuation of primate hematopoietic stem and progenitor cells. Blood 105, 1010-1015. (Pubitemid 40170869)
67. Li, Z., Dullmann, J., Schiedlmeier, B., et al. (2002). Murine leukemia induced by retroviral gene marking. Science 296, 497. (Pubitemid 34408663)
68. Liu, H.S., Jan, M.S., Chou, C.K., et al. (1999). Is green fluorescent protein toxic to the living cells? Biochem. Biophys. Res. Commun. 260, 712-717.
69. Magg, T., Hartrampf, S., and Albert, M.H. (2009). Stable nonviral gene transfer into primary human T cells. Hum. Gene Ther. 20, 989-998.
70. Malech, H.L., Maples, P.B., Whiting-Theobald, N., et al. (1997). Prolonged production of NADPH oxidase-corrected granulo-cytes after gene therapy of chronic granulomatous disease. Proc. Natl. Acad. Sci. U. S. A. 94, 12133-12138. (Pubitemid 27467855)
71. Metais, J.Y., and Dunbar, C.E. (2008). The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. Mol. Ther. 16, 439-449. (Pubitemid 351314981)
72. Mitchell, R.S., Beitzel, B.F., Schroder, A.R., et al. (2004). Retro-viral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, E234.
73. Modlich, U., Kustikova, O.S., Schmidt, M., et al. (2005). Leuke-mias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis. Blood 105, 4235-4246. (Pubitemid 40720768)
74. Modlich, U., Bohne, J., Schmidt, M., et al. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108, 2545-2553.
75. Montini, E., Cesana, D., Schmidt, M., et al. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol. 24, 687-696. (Pubitemid 43882120)
76. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129. (Pubitemid 44547756)
77. Morris, J.C., Conerly, M., Thomasson, B., et al. (2004). Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. Blood 103, 492-499. (Pubitemid 38140079)
78. Newrzela, S., Cornils, K., Li, Z., et al. (2008). Resistance of mature T cells to oncogene transformation. Blood 112, 2278-2286.
79. Nienhuis, A.W., Dunbar, C.E., and Sorrentino, B.P. (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031-1049. (Pubitemid 43779188)
80. Ott, M.G., Schmidt, M., Schwarzwaelder, K., et al. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
81. Persons, D.A., Allay, J.A., Allay, E.R., et al. (1997). Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90, 1777-1786. (Pubitemid 27377287)
82. Persons, D.A., Allay, J.A., Riberdy, J.M., et al. (1998). Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells. Nat. Med. 4, 1201-1205. (Pubitemid 28468837)
83. Qasim, W., Mackey, T., Sinclair, J., et al. (2007). Lentiviral vectors for T-cell suicide gene therapy: preservation of T-cell effector function after cytokine-mediated transduction. Mol. Ther. 15, 355-360. (Pubitemid 46111886)
84. Recchia, A., Bonini, C., Magnani, Z., et al. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U. S. A. 103, 1457-1462. (Pubitemid 43191187)
85. Rettig, M.P., Ritchey, J.K., Prior, J.L., et al. (2004). Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation. J. Immunol. 173, 3620-3630. (Pubitemid 39280721)
86. Rill, D.R., Moen, R.C., Buschle, M., et al. (1992). An approach for the analysis of relapse and marrow reconstitution after au-tologous marrow transplantation using retrovirus-mediated gene transfer. Blood 79, 2694-2700.
87. Rooney, C.M., Smith, C.A., Ng, C.Y., et al. (1995). Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345, 9-13.
88. Rosenberg, S.A., and Dudley, M.E. (2009). Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 21, 233-240.
89. Rosenberg, S.A., Aebersold, P., Cornetta, K., et al. (1990). Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. 323, 570-578. (Pubitemid 20260084)
90. Rosenzweig, M., Macvittie, T.J., Harper, D., et al. (1999). Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood 94, 2271-2286. (Pubitemid 29467675)
91. Schmidt, M., Zickler, P., Hoffmann, G., et al. (2002). Polyclonal long-term repopulating stem cell clones in a primate model. Blood 100, 2737-2743.
92. Seggewiss, R., Pittaluga, S., Adler, R.L., et al. (2006). Acute my-eloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107, 3865-3867. (Pubitemid 43726789)
93. Shepherd, B.E., Kiem, H.P., Lansdorp, P.M., et al. (2007). He-matopoietic stem-cell behavior in nonhuman primates. Blood 110, 1806-1813. (Pubitemid 47443891)
94. \+ hematopoi-etic stem/progenitor cells, using the Sleeping Beauty trans-poson system. Hum. Gene Ther. 20, 1607-1626.
95. Tahvanainen, J., Pykalainen, M., Kallonen, T., et al. (2006). Enrichment of nucleofected primary human CD4\+ T cells: a novel and efficient method for studying gene function and role in human primary T helper cell differentiation. J. Immunol. Methods 310, 30-39. (Pubitemid 43375973)
96. Tey, S.K., Dotti, G., Rooney, C.M., et al. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13, 913-924. (Pubitemid 47055386)
97. Thrasher, A.J., Hacein-Bey-Abina, S., Gaspar, H.B., et al. (2005). Failure of SCID-X1 gene therapy in older patients. Blood 105, 4255-4257. (Pubitemid 40720770)
98. Tiberghien, P., Cahn, J.Y., Brion, A., et al. (1997). Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation: a phase I-II study. Hum. Gene Ther. 8, 615-624. (Pubitemid 27202052)
99. Tisdale, J.F., Hanazono, Y., Sellers, S.E., et al. (1998). Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 92, 1131-1141. (Pubitemid 28369025)
100. Weber, K., Mock, U., Petrowitz, B., et al. (2010). Lentiviral gene ontology (LeGO) vectors equipped with novel drug-selectable fluorescent proteins: new building blocks for cell marking and multi-gene analysis. Gene Ther. 17, 511-520.
101. Wu, T., Bloom, M.L., Yu, J.M., et al. (1998). Murine bone marrow expressing the neomycin resistance gene has no competitive disadvantage assessed in vivo. Hum. Gene Ther. 9, 1157-1164. (Pubitemid 28269001)
102. \+ hema-topoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood 114, 1319-1330.
103. Zychlinski, D., Schambach, A., Modlich, U., et al. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. [Epub ahead of print Feb. 19.]